Published September 26, 2018 | Version v1
Dataset Open

Finding an antibody to detect EZH1 protein expression – Part 3

Creators

  • 1. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network
  • 2. Structural Genomics Consortium, University of Toronto
  • 3. Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • 4. Structural Genomics Consortium, Princess Margaret Cancer Centre, University Health Network, University of Toronto

Description

Follow up to previous post of trying to find an antibody to determine EZH1 expression in AML patient cells.

Notes

The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. This project receives funding from the Leukemia and Lymphoma Society of Canada.

Files

8-30-18_EZH1_antibody_optimization_part 3.pdf

Files (794.6 kB)

Name Size Download all
md5:08248e62917408f971a77f114397f374
492.7 kB Download
md5:69da491ecf2ef7f88409a264cf718bc4
301.8 kB Preview Download